$29.320
-1.117 (-3.81%)收盤時
BEAM 資訊
BEAM 事件
Beam Therapeutics Doses First Patient in BEAM-302 Trial
"The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam," said John Evans, chief executive officer of Beam Therapeutics. "Importantly, this progress enabled dosing of the first patient in the global pivotal cohort evaluating BEAM-302, the most advanced genetic medicine in development for AATD, which has the potential to fundamentally change the treatment paradigm for patients. In addition, we completed dosing for all adult and adolescent SCD patients in the BEACON trial of risto-cel and received FDA clearance of the IND for BEAM-304 in PKU, paving the way to the clinic for this next potentially high-value franchise. Looking ahead, we believe Beam is positioned to achieve several important milestones, including updated clinical data for BEAM-302 at the ERS Congress, rapid enrollment in the BEAM-302 pivotal cohort, first-in-human data for BEAM-301 in GSDIa, and the expected BLA submission for risto-cel. With the continued expansion and advancement of our base editing pipeline, we have the potential to deliver transformative therapies for many patients with serious genetic diseases."
Stocks Broadly Down as Oil Prices Surge
Stocks spent the session broadly in the red as oil prices surged once again after the U.S. launched new strikes on Iran, with President Trump saying the ceasefire is "over." WTI crude oil futures settled at $73.52 per barrel, up over 4%, on fears that renewed hostilities and attacks near the Strait of Hormuz could disrupt global energy supplies. The rally boosted shares of oil producers, while weighing on airlines, cruise operators and other travel-related stocks that are sensitive to higher fuel costs.Meanwhile, the Federal Reserve released the minutes from its last meeting, in which it said a "few" members saw the case for a June rate hike, though those participants indicated that they supported maintaining the current target range at this meeting. Additionally, the Fed said in the minutes that most participants remarked on scenarios in which inflationary pressures would dissipate and inflation would soon begin to return to 2%. In such scenarios, almost all of these participants noted that it would likely be appropriate to maintain or eventually lower the target range for the federal funds rate.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:After U.S. Central Command launched strikes on targets in Iran in response to its attacks on commercial vessels passing through the Strait of Hormuz, U.S. President Donald Trump said that the U.S.Appleannounced awith Broadcomto design and produce custom silicon components and cutting-edge wireless connectivity technologiesDream Finders HomeshasBeazer Homesfor $32 per shareChina will allow top AI companies to buy some NvidiaH200 chips,A "few" Federal Reserve members said they saw the case for a June rate increase, though they also supported maintaining the current target range,2. WALL STREET CALLS:Dollar Treeto Outperform at Raymond James and to Neutral at Goldman SachsOccidentalto Outperform at Evercore ISIBarclaysCommunity Healthto Underweight while also downgrading HCA Healthcareand Universal Healthto Equal WeightBath & Body Worksto Sell at Goldman SachsJPMorganOllie's Bargain Outletto Neutral, sees Q2 miss3. AROUND THE WEB:Hunterbrook published a short report on Bloom Energy, though the company told Bloomberg it plans to "correct the record"OpenAI will publicly launch GPT-5.6, its most advanced AI model, on Thursday following a delay last month prompted by U.S. government requests over heightened national security concerns about the potential misuse of powerful AI technologies, Reuters saysJPMorgan Chaseis planning to target small-company deals, establishing a new team of investment bankers focused on small-cap companies valued between $100M-$500M, WSJ reportsSK Hynix's$28B ADR offering is seeing strong investor demand, with orders oversubscribing the deal ahead of pricing and allocation later in the week, Reuters saysLast week, Tate Bennett, chief of staff for USDA Secretary Brooke Rollins, spoke with grocers including Walmart, Kroger, and Albertsonsasking about their prices for beef heading into the holiday weekend, WSJ reports4. MOVERS:Prime Medicinegained after the company reported awith Beam TherapeuticsPenguin Solutionswas higher afterand increasing its guidance for FY26Redwireincreased after appointing Paul Reichert and Niki WerkheiserFuelCellwas lower after announcing aNavitasfell after Wolfspeedfiled aagainst the company5. EARNINGS/GUIDANCE:Helen of Troyand reaffirmed its guidance for FY27Sono-Tek, with the company commenting, "Fiscal 2027 is off to a strong start"Palladyne AIreportedHyperscale Databacked itsEnerpac Toolsand raised its guidance for FY26INDEXES:The Dow fell 576.76, or 1.09%, to 52,348.39, the Nasdaq gained 51.96, or 0.20%, to 25,870.65, and the S&P 500 declined 21.14, or 0.28%, to 7,482.71.
Prime Medicine and Beam Therapeutics Reach Positive Arbitration Resolution
Prime Medicine (PRME) earlier announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics (BEAM) relating to the parties' 2019 Collaboration and License Agreement. "The Tribunal declared that PM647, Prime Medicine's investigational Prime Editing drug for Alpha-1 Antitrypsin Deficiency , is within Prime Medicine's 'Field' as defined by the Agreement, and that Prime Medicine therefore did not breach the Agreement. Prime Medicine owes no monetary damages to Beam Therapeutics," the company stated. "Our goal has always been to leverage the Prime Platform to develop differentiated medicines for patients. We believe Prime Editing is the optimal approach to correcting the genetic cause of AATD by restoring normal protein function. We are pleased with the Tribunal's decision, which paves the way for PM647 to advance into the clinic and positions us to fully realize PM647's potential for patients. With PM577a for Wilson Disease now cleared to enter the clinic and PM647 approaching an IND and/or CTA filing, we are focused on bringing potentially curative therapies to patients with two of the largest genetic liver diseases," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine.
Beam Therapeutics BEAM-304 Receives FDA Approval
Beam Therapeutics announced that the United States Food and Drug Administration, FDA, has cleared the investigational new drug, IND, application for BEAM-304 for the treatment of phenylketonuria, PKU. PKU is a rare, inherited metabolic disorder that results in toxic accumulation of phenylalanine, leading to serious neurologic and neurocognitive impairments and requires strict, lifelong dietary management. Beam is advancing BEAM-304 using an innovative development approach in which multiple mutation-specific base editors are developed efficiently within a single clinical program using in vivo delivery, in accordance with the FDA's recent efforts to accelerate development of genome editing therapies.1
Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B
Jeff Bezos' new AI venture Prometheus has raised $12B in fresh funding, pushing its valuation to about $41B. Meanwhile, OpenAI confidentially filed for an IPO with the SEC, setting up a potential race with Anthropic as both companies seek massive new capital.This week's private company news:OpenAI announced that it will acquire Ona, "bringing its secure cloud execution and orchestration technology into our rapidly expanding Codex ecosystem." OpenAI said: "As Codex becomes more capable, its most valuable work is unfolding over hours or days, rather than minutes. We believe people should be able to delegate more ambitious work without remaining tied to the machine where it began. The work should continue beyond the initial session, with Codex making it possible to stay connected and check progress, provide direction, make decisions, and review results from anywhere. Ona will help us do that. Its technology provides secure, persistent environments where agents can access the tools, systems, and context they need to make progress over time."Sam Altman, CEO of Microsoft-backed OpenAI, and the Trump administration are in ongoing discussions over a possible government stake in the ChatGPT maker, CNBC's Ashley Capoot and Kate Rooney. The talks have been in progress for over a year, as Altman first shared the idea with the White House last year, the authors say, citing a source familiar with the matter. Such discussions continued this week as the CEO met with a number of lawmakers and officials in Washington, D.C. to go over regulation and the latest developments in AI, the authors note. As part of a potential pact, OpenAI could donate equity to the U.S. government to seed something in the vein of a "Public Wealth Fund" that the ChatGPT maker outlined in its April policy proposal, the authors say.Some of the biggest capital raises by private companies this week include:Prometheus- Jeff Bezos' newest AI venture has secured a massive $12B funding round. Prometheus launched in November with $6.2B in initial backing and is now valued at roughly $41B. The latest funding round includes investments from JPMorgan Chase, Goldman Sachsand BlackRock. Publicly-traded companies operating in the same space include Microsoft, IBM, and Palantir.NEURA Robotics– The cognitive robotics company and creator of the Neuraverse announced a Series C financing with a total round size of up to $1.4B to accelerate its mission of building the world's leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure, including Tether, Qualcomm, Amazon, Nvidia, imec.xpand, Bosch, Schaeffler, European Investment Bank, Lingotto Horizon, InterAlpen Partners and others. Publicly-traded companies operating in the same space include Tesla, Symbotic, and iRobot.Cyera– The cybersecurity startup raised $600M at a $12B valuation in a round led by Evolution Equity Partners, with participation from Cyberstarts and Temasek, in addition to all existing investors including Accel, AT&T Ventures, Blackstone, Coatue, Spark Capital, among others. Publicly-traded companies operating in the same space include Palo Alto Networks, CrowdStrike, and Fortinet.Flourish– The company said it raised $500M at a $2.5B valuation, with Amazonfounder Jeff Bezos contributing nearly $100M. Publicly-traded companies operating in the same space include AeroVironment.Helion– The Washington-based fusion energy company announced a $465M Series G investment round that was led by Thrive Capital. Publicly-traded companies operating in the same space include Chevron, Nucor, and AMSC.Unicorns to watch this week:Insilico Medicine– The AI-driven drug discovery startup recently raised to unicorn status with its latest funding round. The company uses generative AI to design small molecule drugs and accelerate preclinical development. Publicly-traded companies operating in the same space include Exscientiaand Recursion Pharmaceuticals.Innovaccer– The healthcare AI unicorn, valued at about $3.45B, is focusing on acquisitions and secondary rounds as it expands its healthcare data and analytics platform. Publicly-traded companies operating in the same space include Phreesia, IQVIA, and CareCloud.Dataiku– The AI/machine-learning platform helps enterprises build, deploy and manage models. Publicly-traded companies operating in the same space include Altair, Google, and IBM.Mammoth Biosciences– The company focuses on CRISPR-based diagnostics and therapeutics, using novel CRISPR systems. Publicly-traded companies operating in the same space include CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics.Apex Space– The space company, which builds satellite platforms for commercial and government customers, recently reached unicorn status as demand for space based networks accelerates. Publicly-traded companies operating in the same space include Redwire, AST SpaceMobile, and Iridium Communications.Other IPOs to watch:OpenAI– The company has confidentially filed for an IPO with the SEC, which allows the company to submit its financials to regulators for review before they're made available to the public, CNBC.com's Ashley Capoot. Anthropic and OpenAI could be in a race to go public due to the massive amount of capital they're trying to raise, the report states.Bending Spoons– The technology company whose main businesses include AOL, Brightcove, Eventbrite, Evernote, Harvest, komoot, Remini, StreamYard, Vimeo, and WeTransfer announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol "BSP."Kardigan– The company has filed an initial public offering of shares of its common stock. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "KARD." JP Morgan, Jefferies, Leerink Partners, and TD Cowen are acting as the underwriters for the offering.SpaceX– The company has officially submitted its Form S-1 with the SEC to list its Class A common stock on the Nasdaq under the ticker symbol SPCX. Expected to be the largest IPO in history, the company targets raising up to $80B at a valuation exceeding $2T.Inspire Brands– The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses."Private Markets" is The Fly's recurring series of stories on the latest moves in the private sector, largest unicorn companies and initial public offerings to watch. Fly subscribers, add $PRIVATE to your portfolio for alerts on breaking news in the startup and venture capital space.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。